ISB News

TCGA, ISB Researchers Identify Potential Drug Targets for Leading Form of Deadly Liver Cancer

June 19, 2017

Researchers in ISB’s Shmulevich Lab and their colleagues in The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer. Study was published on June 15, 2017, in the journal Cell.

3 Bullets:

  • Liver cancer is the second most common cause of death from cancer worldwide.
  • ISB researchers and colleagues from The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer.
  • Such integrated analyses enabled the identification of potential therapeutic targets and facilitated biological insights that would not have been possible otherwise.

READ THE SUMMARY AND PAPER

 

Recent Articles

  • New Research Unveils Effective STEM Program Models for High School Students from Historically Marginalized Communities

    An ISB-led study has unveiled important insights and actionable protocols into providing equitable STEM experiences for high school students from historically marginalized communities. The research highlights the transformative power of informal STEM learning in addressing societal challenges and the ease with which many organizations could provide these important opportunities.

  • Common Immune Response Protective Across Many Diseases

    Combined, infection, autoimmunity and cancer account for 40 percent of deaths worldwide and represent major global health challenges. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases. Their findings offer promising avenues for exploring multi-disease therapeutic strategies.

  • Spotlight on ISB Education graphic

    2023-24 School Year ISB Education Highlights

    Each month throughout the 2023-2024 academic year, we will highlight some of the top projects the ISB Education team is working on.